WallStreetZenWallStreetZen

NASDAQ: LTGO
Latigo Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LTGO

Based on 3 analysts offering 12 month price targets for Latigo Biotherapeutics Inc

Min Forecast
$36.00+174.6%
Avg Forecast
$45.33+245.79%
Max Forecast
$50.00+281.39%

Should I buy or sell LTGO stock?

Based on 3 analysts offering ratings for Latigo Biotherapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LTGO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LTGO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their LTGO stock forecasts and price targets.

LTGO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-01
lockedlocked$00.00+00.00%2026-09-01
lockedlocked$00.00+00.00%2026-09-01

1 of 1

Forecast return on equity

Is LTGO forecast to generate an efficient return?

Company
-49.69%
Industry
-34.22%
Market
145.13%
LTGO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LTGO forecast to generate an efficient return on assets?

Company
-47.93%
Industry
-2.38%
LTGO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LTGO earnings per share forecast

What is LTGO's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$2.96
Avg 2 year Forecast
-$2.34
Avg 3 year Forecast
-$2.95

LTGO revenue forecast

What is LTGO's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$21.4M

LTGO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LTGO$13.11$45.33+245.79%Strong Buy
IVA$3.68$16.75+355.16%Strong Buy
SNDX$9.45$36.33+284.48%Strong Buy
PHAR$12.60$39.00+209.52%Strong Buy
MGTX$9.18$21.00+128.76%Buy
View Top Biotech Stocks

Latigo Biotherapeutics Stock Forecast FAQ

Is Latigo Biotherapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: LTGO) stock is to Strong Buy LTGO stock.

Out of 3 analysts, 2 (66.67%) are recommending LTGO as a Strong Buy, 1 (33.33%) are recommending LTGO as a Buy, 0 (0%) are recommending LTGO as a Hold, 0 (0%) are recommending LTGO as a Sell, and 0 (0%) are recommending LTGO as a Strong Sell.

If you're new to stock investing, here's how to buy Latigo Biotherapeutics stock.

What is LTGO's earnings growth forecast for 2026-2028?

(NASDAQ: LTGO) Latigo Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.2%.

Latigo Biotherapeutics's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast LTGO's earnings for 2026 to be -$196,113,468, with the lowest LTGO earnings forecast at -$272,238,379, and the highest LTGO earnings forecast at -$146,886,203. On average, 6 Wall Street analysts forecast LTGO's earnings for 2027 to be -$154,862,015, with the lowest LTGO earnings forecast at -$179,326,474, and the highest LTGO earnings forecast at -$136,444,056.

In 2028, LTGO is forecast to generate -$195,775,342 in earnings, with the lowest earnings forecast at -$294,979,055 and the highest earnings forecast at -$155,239,921.

What is LTGO's revenue growth forecast for 2026-2028?

(NASDAQ: LTGO) Latigo Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 42.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.75%.

Latigo Biotherapeutics's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast LTGO's revenue for 2026 to be $0, with the lowest LTGO revenue forecast at $0, and the highest LTGO revenue forecast at $0. On average, 6 Wall Street analysts forecast LTGO's revenue for 2027 to be $0, with the lowest LTGO revenue forecast at $0, and the highest LTGO revenue forecast at $0.

In 2028, LTGO is forecast to generate $1,417,546,338 in revenue, with the lowest revenue forecast at $415,829,504 and the highest revenue forecast at $3,480,715,718.

What is LTGO's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: LTGO) forecast ROA is -47.93%, which is lower than the forecast US Biotechnology industry average of -2.38%.

What is LTGO's Price Target?

According to 3 Wall Street analysts that have issued a 1 year LTGO price target, the average LTGO price target is $45.33, with the highest LTGO stock price forecast at $50.00 and the lowest LTGO stock price forecast at $36.00.

On average, Wall Street analysts predict that Latigo Biotherapeutics's share price could reach $45.33 by Sep 1, 2027. The average Latigo Biotherapeutics stock price prediction forecasts a potential upside of 245.79% from the current LTGO share price of $13.11.

What is LTGO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LTGO) Latigo Biotherapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that LTGO's EPS will be -$2.96 for 2026, with the lowest EPS forecast at -$4.11, and the highest EPS forecast at -$2.22. On average, analysts forecast that LTGO's EPS will be -$2.34 for 2027, with the lowest EPS forecast at -$2.70, and the highest EPS forecast at -$2.06. In 2028, LTGO's EPS is forecast to hit -$2.95 (min: -$4.45, max: -$2.34).

What is LTGO's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: LTGO) forecast ROE is -49.69%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.